Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement.

Area of Science:

• * Public Health
• * Vaccinology
• * Epidemiology

Background:

• * Pneumococcal conjugate vaccination (PCV) effectively reduces vaccine-type pneumococcal carriage and disease.
• * Serotype replacement, where non-vaccine types increase post-vaccination, poses a significant challenge to PCV programs.
• * Optimizing vaccine serotype composition is crucial to maximize public health impact and mitigate replacement effects.

Purpose of the Study:

• * To develop a quantitative tool for assessing the impact of serotype replacement on PCV effectiveness against invasive pneumococcal disease (IPD).
• * To guide the selection of optimal pneumococcal vaccine serotype compositions for different age groups.
• * To evaluate the potential for improving overall vaccine effectiveness through strategic serotype inclusion.

Main Methods:

• * Utilized pre-vaccination data on pneumococcal carriage and IPD incidence.
• * Employed a predictive model incorporating assumptions on vaccine-type carriage elimination, non-vaccine type replacement, and stable case-to-carrier ratios.
• * Developed a sequential algorithm to identify optimal serotype compositions and assessed model robustness.

Main Results:

• * Predicted a 75% decrease in IPD for children <5 years with current PCV compositions, but only 20-40% in older populations due to serotype replacement and herd effects.
• * Identified that optimal serotype composition is age-dependent, with some serotypes beneficial for children but not adults.
• * Demonstrated that current PCV serotype compositions are suboptimal, with potential for improvement by including serotypes like 22 and 9N.

Conclusions:

• * Pneumococcal conjugate vaccination effectiveness can be significantly enhanced by optimizing serotype composition to counteract serotype replacement.
• * The inclusion of specific non-vaccine serotypes with high case-to-carrier ratios can improve net vaccine effectiveness.
• * Future PCV formulations should consider age-specific epidemiology and replacement dynamics for maximal population benefit.